These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 8625553)

  • 1. Procainamide-induced agranulocytosis differs serologically and clinically from procainamide-induced lupus.
    Starkebaum G; Kenyon CM; Simrell CR; Creamer JI; Rubin RL
    Clin Immunol Immunopathol; 1996 Feb; 78(2):112-9. PubMed ID: 8625553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IgG but not other classes of anti-[(H2A-H2B)-DNA] is an early sign of procainamide-induced lupus.
    Rubin RL; Burlingame RW; Arnott JE; Totoritis MC; McNally EM; Johnson AD
    J Immunol; 1995 Mar; 154(5):2483-93. PubMed ID: 7868914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IgG antibodies to the histone complex H2A-H2B characterize procainamide-induced lupus.
    Rubin RL; McNally EM; Nusinow SR; Robinson CA; Tan EM
    Clin Immunol Immunopathol; 1985 Jul; 36(1):49-59. PubMed ID: 3874029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoantibodies associated with lupus induced by diverse drugs target a similar epitope in the (H2A-H2B)-DNA complex.
    Rubin RL; Bell SA; Burlingame RW
    J Clin Invest; 1992 Jul; 90(1):165-73. PubMed ID: 1378852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of antibody to histone complex H2A-H2B with symptomatic procainamide-induced lupus.
    Totoritis MC; Tan EM; McNally EM; Rubin RL
    N Engl J Med; 1988 Jun; 318(22):1431-6. PubMed ID: 3259287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autoantibody specificity in drug-induced lupus and neutrophil-mediated metabolism of lupus-inducing drugs.
    Rubin RL
    Clin Biochem; 1992 Jun; 25(3):223-34. PubMed ID: 1633638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoantibody to the nucleosome subunit (H2A-H2B)-DNA is an early and ubiquitous feature of lupus-like conditions.
    Burlingame RW; Rubin RL
    Mol Biol Rep; 1996; 23(3-4):159-66. PubMed ID: 9112224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-induced anti-histone autoantibodies display two patterns of reactivity with substructures of chromatin.
    Burlingame RW; Rubin RL
    J Clin Invest; 1991 Aug; 88(2):680-90. PubMed ID: 1864977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acetylation status is associated with serological changes but not clinically significant disease in patients receiving procainamide.
    Mongey AB; Sim E; Risch A; Hess E
    J Rheumatol; 1999 Aug; 26(8):1721-6. PubMed ID: 10451068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Agranulocytosis caused by procainamide.
    Hickson B; Davidson RJ; Walker W
    Scott Med J; 1972 May; 17(5):165-8. PubMed ID: 4537437
    [No Abstract]   [Full Text] [Related]  

  • 11. In vitro production of antibodies to histones in patients receiving chronic procainamide therapy.
    Mongey AB; Hess E
    J Rheumatol; 2001 Sep; 28(9):1992-8. PubMed ID: 11550965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiguanosine antibodies: a new marker for procainamide-induced systemic lupus erythematosus.
    Weisbart RH; Yee WS; Colburn KK; Whang SH; Heng MK; Boucek RJ
    Ann Intern Med; 1986 Mar; 104(3):310-3. PubMed ID: 3511820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Procainamide elicits a selective autoantibody immune response.
    Rubin RL; Reimer G; McNally EM; Nusinow SR; Searles RP; Tan EM
    Clin Exp Immunol; 1986 Jan; 63(1):58-67. PubMed ID: 3485487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serologic evaluation of patients receiving procainamide.
    Mongey AB; Donovan-Brand R; Thomas TJ; Adams LE; Hess EV
    Arthritis Rheum; 1992 Feb; 35(2):219-23. PubMed ID: 1734911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-myeloid-cell antibody in procainamide-induced agranulocytosis.
    Azócar J
    Lancet; 1984 May; 1(8385):1069-70. PubMed ID: 6143992
    [No Abstract]   [Full Text] [Related]  

  • 16. Procainamide-induced lupus erythematosus-like syndrome in relation to acetylator phenotype and plasma levels of procainamide.
    Sonnhag C; Karlsson E; Hed J
    Acta Med Scand; 1979; 206(4):245-51. PubMed ID: 92167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoantibodies to histone, DNA and nucleosome antigens in canine systemic lupus erythematosus.
    Monestier M; Novick KE; Karam ET; Chabanne L; Monier JC; Rigal D
    Clin Exp Immunol; 1995 Jan; 99(1):37-41. PubMed ID: 7529150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Procainamide-induced agranulocytosis.
    Reidy TJ; Upshaw JD
    South Med J; 1984 Dec; 77(12):1582-4. PubMed ID: 6505768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-[(H2A/2B)-DNA]] IgG supports the diagnosis of procainamide-induced arthritis or pleuritis.
    Lau CC; Clos TD
    Arthritis Rheum; 1999 Jun; 42(6):1300-1. PubMed ID: 10366129
    [No Abstract]   [Full Text] [Related]  

  • 20. Scleritis as the presenting manifestation of procainamide-induced lupus.
    Turgeon PW; Slamovits TL
    Ophthalmology; 1989 Jan; 96(1):68-71. PubMed ID: 2645552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.